Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...
Ron Lanton, Partner, Lanton Law, discusses how stakeholders must navigate funding future clinical research amid NIH budget cuts.
Beyond direct costs, CROs incur significant expenses in the pre-award phase, creating strategic proposals to compete for trial contracts from sponsors. These activities, often unpaid, cost millions ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest ...
A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...
External control arms, as an integral part of clinical development, present many potential opportunities for sponsors and ...
In this video interview, Pomerantseva, director of product management, RBQM, eClinical Solutions, discusses the new guidance ...
Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...
In this video interview, Dominique Demolle, CEO of Cognivia, talks artificial intelligence/machine learning and its potential ...
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, highlights FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback